RDHLRedHill Biopharma Ltd.
$0.8383
$0.0151
(1.79%)
Closed $0.8299
$0.0084
(1.01%)
After Hours
Mkt Cap$4.31M
Vol50,882.00
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement PR Newswire TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 $6 million upfront with up to approximately $13.4 million of potential aggregate...
PR Newswire
RedHill Biopharma Announces Up To $19.4 Million Private Placement
RedHill Biopharma Announces Up To $19.4 Million Private Placement RedHill Biopharma Announces Up To $19.4 Million Private Placement PR Newswire TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 $6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the...
PR Newswire
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation PR Newswire RALEIGH, N.C. and...
PR Newswire
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 RALEIGH, N.C.and TEL-AVIV, Israel, June 8...
PR Newswire
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense...
PR Newswire
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease RedHill's RHB-204 Demonstrates Comparable MAP Killing...
PR Newswire
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights PR Newswire TEL AVIV...
PR Newswire
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity...
PR Newswire
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) DelveInsight
H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight H. pylori Infections Market in the 6MM to Observe...
PR Newswire
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) DelveInsight
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight Biliary Tract Cancer Market is Predicted to Exhibit...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest RDHL News
ViewRedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
PR Newswire
RedHill Biopharma Announces Up To $19.4 Million Private Placement
PR Newswire
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
PR Newswire
Advertisement|Remove ads.